FDA
-
-
-
-
-
-
-
Bayer receives FDA approval for lowest-dose MRI contrast agent
-
-
-
-
-
-
-
Bayer's KERENDIA gets FDA priority review for type 1 diabetes treatment
-
-
-
-
-
-
-
UBS Reiterates Buy Rating on Bayer AG (BAYN:GR) (BAYRY)
-
-
-
-
-
-
-
Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus
-
-
-
-
-
-
-
Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations
-
-
-
-
-
-
-
One A Day® Unveils Bold New Brand Identity and Platform: “The ONE for you”
-
-
-
-
-
-
-
Judge Appoints Four Attorneys to Lead 77,000 Zantac Cancer Cases in Delaware
-
330,737 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

